# Advisor Review - GPT-5.4 (R2)

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T14:28:02.028414
**Route:** OpenRouter + LaTeX
**Paper Hash:** cb13bcbf20050003
**Tokens:** 21079 in / 1947 out
**Response SHA256:** d36530a6fb27cac3

---

I checked the paper for fatal errors in the four requested categories and did not find any that would make the empirical design impossible, the regression output obviously broken, the paper incomplete, or the core reported numbers internally contradictory.

Checks performed:

- **Data-design alignment**
  - Main treatment is the **2018 REACH deadline**; data cover **2008–2020**, so treatment year is within sample.
  - Main DDD has post-treatment observations for 2018, 2019, and 2020.
  - 2013 placebo uses sample **2008–2017**, so it also has post-treatment observations.
  - Treatment timing definitions appear consistent across abstract, text, tables, and appendix.

- **Regression sanity**
  - Reviewed all reported regression tables: Tables **\ref{tab:main}, \ref{tab:placebo}, \ref{tab:loo}, \ref{tab:alt_controls}, \ref{tab:timing}, \ref{tab:emp_robust}, \ref{tab:size_class}, \ref{tab:sde}**.
  - No impossible or obviously broken outputs:
    - no negative standard errors
    - no NA / NaN / Inf in regression results
    - no \(R^2\) outside \([0,1]\)
    - no coefficients or SEs of implausible magnitude by the rules you specified

- **Completeness**
  - Regression tables report **standard errors** and **sample sizes (N/Observations)**.
  - Figures/tables cited in the text appear to exist in the LaTeX source.
  - Methods described in the text have corresponding reported results somewhere in the paper or appendix.
  - No placeholder entries like **TBD, TODO, XXX, NA** in the regression/output tables.

- **Internal consistency**
  - Main numerical claims in text match the reported tables:
    - Main DDD estimates match Table \ref{tab:main}
    - 2013 placebo numbers match Table \ref{tab:placebo}
    - robustness ranges and alternative timing/control claims match appendix tables
  - Sample period, number of countries, sectors, and raw panel size are mutually consistent:
    - \(27 \times 5 \times 13 = 1{,}755\)

I do see some non-fatal issues one could revisit later (for example, some narrative interpretations are stronger than the event-study evidence would usually support, and there are a few descriptive-number tensions in prose), but those are **not** fatal under your screening criteria.

ADVISOR VERDICT: PASS